KR20160130463A - 다량체 Fc 단백질 - Google Patents

다량체 Fc 단백질 Download PDF

Info

Publication number
KR20160130463A
KR20160130463A KR1020167027642A KR20167027642A KR20160130463A KR 20160130463 A KR20160130463 A KR 20160130463A KR 1020167027642 A KR1020167027642 A KR 1020167027642A KR 20167027642 A KR20167027642 A KR 20167027642A KR 20160130463 A KR20160130463 A KR 20160130463A
Authority
KR
South Korea
Prior art keywords
residue
fusion protein
pro
val
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167027642A
Other languages
English (en)
Korean (ko)
Inventor
파르나즈 팔라-아라니
로버트 안토니 그리핀
데이비드 폴 험프리스
셜리 제인 피터스
브라이언 존 스미스
폴 에드워드 스티븐스
Original Assignee
유씨비 바이오파마 에스피알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201403913A external-priority patent/GB201403913D0/en
Priority claimed from GB201403912A external-priority patent/GB201403912D0/en
Priority claimed from GB201405952A external-priority patent/GB201405952D0/en
Priority claimed from GB201412646A external-priority patent/GB201412646D0/en
Application filed by 유씨비 바이오파마 에스피알엘 filed Critical 유씨비 바이오파마 에스피알엘
Publication of KR20160130463A publication Critical patent/KR20160130463A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
KR1020167027642A 2014-03-05 2015-03-05 다량체 Fc 단백질 Withdrawn KR20160130463A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB201403913A GB201403913D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403913.5 2014-03-05
GB201403912A GB201403912D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403912.7 2014-03-05
GB201405952A GB201405952D0 (en) 2014-04-02 2014-04-02 Proteins
GB1405952.1 2014-04-02
GB201412646A GB201412646D0 (en) 2014-07-16 2014-07-16 Proteins
GB1412646.0 2014-07-16
PCT/EP2015/054687 WO2015132364A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (1)

Publication Number Publication Date
KR20160130463A true KR20160130463A (ko) 2016-11-11

Family

ID=52629578

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027642A Withdrawn KR20160130463A (ko) 2014-03-05 2015-03-05 다량체 Fc 단백질

Country Status (15)

Country Link
US (1) US11352414B2 (en:Method)
EP (1) EP3114143B1 (en:Method)
JP (1) JP6851200B2 (en:Method)
KR (1) KR20160130463A (en:Method)
CN (1) CN106068274A (en:Method)
AU (1) AU2015226100B2 (en:Method)
BR (1) BR112016020368A2 (en:Method)
CA (1) CA2939198A1 (en:Method)
IL (1) IL247096A0 (en:Method)
MX (1) MX2016010951A (en:Method)
RU (1) RU2016139006A (en:Method)
SG (1) SG11201606597QA (en:Method)
TW (1) TW201619188A (en:Method)
UY (1) UY36021A (en:Method)
WO (1) WO2015132364A1 (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200008288A (ko) * 2018-07-16 2020-01-28 전북대학교산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
KR102546875B1 (ko) 2014-05-02 2023-06-26 모멘타 파머슈티컬스 인코포레이티드 공학처리된 ｆｃ 작제물과 관련된 조성물 및 방법
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
MX2018008339A (es) * 2016-01-27 2018-09-17 CSL Behring Lengnau AG Multimeros fc de inmunoglobulina g recombinante.
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
IL263211B2 (en) 2016-05-23 2023-09-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered fc constructs
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
BR112019001156A2 (pt) * 2016-07-22 2019-04-30 Gliknik Inc proteínas de fusão de fragmentos de proteína humana para criar composições de fc de imunoglobulina multimerizadas ordenadas com ligação de receptor fc reforçada
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
CN113480654B (zh) 2017-03-28 2022-06-10 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
KR101913743B1 (ko) 2017-04-07 2018-11-01 국민대학교 산학협력단 혈중 반감기 연장을 위한 항체 Fc 변이체들
JP7710827B2 (ja) * 2017-06-05 2025-07-22 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
JP7351835B2 (ja) * 2017-12-14 2023-09-27 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
AU2019235513B2 (en) * 2018-03-16 2026-01-29 Liverpool School Of Tropical Medicine Chimeric Fc receptor binding proteins and uses thereof
CN113271972B (zh) * 2018-11-14 2025-06-17 Jn生物科学有限责任公司 用于替代IVIG的多聚体杂交Fc蛋白
EP4028415A1 (en) 2019-09-13 2022-07-20 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders
WO2021111007A1 (en) * 2019-12-06 2021-06-10 CSL Behring Lengnau AG Stable compositions of fc multimers
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体
IL317568A (en) * 2022-06-10 2025-02-01 Res Found Dev Engineered FCRIIB Selective IgG1 FC Variants, and Their Uses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6114515A (en) 1997-08-25 2000-09-05 Smithkline Beecham Corporation PIGRL-1, a member of immunoglobulin gene superfamily
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY129566A (en) 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US6475749B1 (en) 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE541857T1 (de) 2002-09-27 2012-02-15 Xencor Inc Optimierte fc-varianten und herstellungsverfahren dafür
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1644412T2 (sl) 2003-07-01 2018-11-30 Ucb Biopharma Sprl Modificirani fab fragmenti protiteles
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
MX2009013004A (es) * 2007-06-01 2010-01-20 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
CN102027018A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
EP2389192A4 (en) 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
US20130156765A1 (en) 2010-07-28 2013-06-20 David S. Block FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
KR102208698B1 (ko) 2011-12-21 2021-01-29 암젠 인크 신생아 Fc 수용체에 대해 향상된 결합을 지니는 변이체 Fc-폴리펩타이드
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
MX2015000683A (es) 2012-08-02 2015-04-10 Hoffmann La Roche Metodo para producir moleculas monomericas y multimericas y uso de las mismas.
HK1210792A1 (en) 2012-08-20 2016-05-06 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
US20150218236A1 (en) 2012-10-17 2015-08-06 Liverpool School Of Tropical Medicine Immunomodulatory proteins
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
CN106255704A (zh) 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
KR102546875B1 (ko) 2014-05-02 2023-06-26 모멘타 파머슈티컬스 인코포레이티드 공학처리된 ｆｃ 작제물과 관련된 조성물 및 방법
US20180044416A1 (en) 2015-03-05 2018-02-15 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200008288A (ko) * 2018-07-16 2020-01-28 전북대학교산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도

Also Published As

Publication number Publication date
TW201619188A (zh) 2016-06-01
SG11201606597QA (en) 2016-09-29
CA2939198A1 (en) 2015-09-11
JP6851200B2 (ja) 2021-03-31
RU2016139006A (ru) 2018-04-05
EP3114143B1 (en) 2020-07-08
AU2015226100A1 (en) 2016-08-25
WO2015132364A1 (en) 2015-09-11
JP2017512063A (ja) 2017-05-18
US11352414B2 (en) 2022-06-07
UY36021A (es) 2015-09-30
US20170088603A1 (en) 2017-03-30
CN106068274A (zh) 2016-11-02
MX2016010951A (es) 2016-11-29
AU2015226100B2 (en) 2020-05-07
EP3114143A1 (en) 2017-01-11
IL247096A0 (en) 2016-09-29
BR112016020368A2 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
KR20160130463A (ko) 다량체 Fc 단백질
JP7797198B2 (ja) ヒトｐｄ－１に対する二機能性分子
AU2015226101B2 (en) Multimeric Fc proteins
JP2017513481A (ja) 多量体Ｆｃタンパク質
US20180044416A1 (en) Polymeric Fc proteins and methods of screening to alter their functional characteristics
KR20230029621A (ko) T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
CN113557245A (zh) 人源化的抗人pd-1抗体
JP2022514702A (ja) 二機能性抗ｐｄ－１／ｉｌ－７分子
WO2017036905A1 (en) Multimeric proteins which bind to human fc-receptors
WO2020165374A1 (en) Bifunctional molecule comprising il-15ra
CN120757645A (zh) 抗cd38抗体和配制品
JP2025535041A (ja) 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
US20260049141A1 (en) Multifunctional molecule directed against cd28

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161005

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination